Organovo Logo     Print Page | Close Window

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
Chairperson Chairperson Committee Member Member Financial Expert Financial Expert
 Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee
Independent Director
Robert Baltera, Jr., M.S., M.B.A. Financial Expert
Robert Baltera, Jr., M.S., M.B.A.
Director


Mr. Baltera is the CEO of Laguna Pharmaceuticals. A seasoned pharmaceutical industry executive, Mr. Baltera acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. In his recent role as CEO of Amira Pharmaceuticals, he led the company to acquisition by Bristol-Meyers Squibb Company. He was instrumental in focusing Amira’s development efforts, strengthening and developing its pipeline and forging key collaborations with partners such as GlaxoSmi... 
Committee Member Chairperson  
James T. Glover, M.B.A., C.P.A. Financial Expert
James T. Glover, M.B.A., C.P.A.
Director


Mr. Glover, our audit committee chairman, was formerly Senior Vice President and Chief Financial Officer of Beckman Coulter, Inc., and was also Senior Vice President of Operations and Chief Financial Officer of Anadys Pharmaceuticals, Inc, a publicly traded pharmaceutical company later acquired by Roche. Mr. Glover served on the Board of Directors and as audit committee chairman of Varian, Inc. until its acquisition by Agilent in 2010. Mr. Glover received his B.S. in accounting from California S... 
Chairperson Committee Member Committee Member
Tamar D. Howson, M.S., M.B.A. Financial Expert
Tamar D. Howson, M.S., M.B.A.
Director


Ms. Howson is a seasoned business development executive within the pharmaceutical industry. She currently serves as a corporate business development and strategy consultant to biopharmaceutical companies and she serves as a director at Oxigene Pharmaceuticals. She also served as a director at Warner Chilcott and Idenix, which were acquired in 2013 and 2014, respectively. Previously, she was a member of the transaction advisory firm, JSB Partners. Prior to that, she was senior vice president of C... 
Committee Member Committee Member  
Mark Kessel, J.D. 
Mark Kessel, J.D.
Director


Mr. Kessel is a partner of Symphony Capital, LLC, a private equity firm he co-founded in 2002 that invests in biopharmaceutical company clinical development programs. He is also Of Counsel at Shearman & Sterling and a member of the firm’s capital markets group. Previously, from 1971 to 2001, Mr. Kessel held various roles at Shearman & Sterling, including as managing partner leading the international law firm’s day-to-day operations. He helped build the firm, serving as a leader in the healthcare... 
   Committee Member
Kirk Malloy, Ph.D. 
Kirk Malloy, Ph.D.
Director


Dr. Malloy has held management and executive leadership positions in rapidly growing life science and diagnostics companies for 18 years. He is currently Senior Vice President and General Manager of Life Sciences at Illumina, a leading developer and supplier of genetic analysis instrumentation, assays and software for the life science and diagnostics markets. At Illumina, Dr. Malloy oversees the company’s core platform technologies and the core life sciences markets they enable. He joined Illumi... 
   Chairperson
Richard Maroun, J.D. Financial Expert
Richard Maroun, J.D.
Director


Richard Maroun is an executive partner at Frazier Healthcare Partners, a private equity and venture capital firm specializing in healthcare-focused investments. Before joining Frazier in 2015, Maroun was senior vice president and general counsel of Aptalis Pharmaceuticals from 2012 to 2014. He has also held numerous senior executive roles for APP Pharmaceuticals, Abraxis BioScience and American BioScience Inc. Mr. Maroun has worked with major financial organizations and independent law firms, an... 
Committee Member Committee Member  
Non-Independent Director
Taylor Crouch 
Taylor Crouch
Director
   
Keith Murphy 
Keith Murphy
Chairman and Chief Executive Officer


Mr. Murphy has more than 20 years of experience in biotechnology, including co-founding Organovo in 2007 and serving in Product Strategy and Director of Process Development roles at Amgen. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Al...